Piramal Pharma shares witnessed a surge of nearly 2%, since the morning hours on Thursday. The USFDA has issued an Establishment Inspection Report for the company’s Riverview manufacturing facility.
The inspection took place on February 7, 2024, and has now been concluded with the issuance of the EIR.
Remaining a positive development for Piramal Phamera means that the US regulator has found the manufacturing facility to be compliant with the regulations and standards.
This is a significant development for the overall operations of Piramal Pharma as the Riverview facility is an important one.
As of 10:23 am, . the company stock was trading higher by 1.77%. at Rs 143.85, on the NSE.
